Home Page

DALLAS, Oct. 2, 2015 /PRNewswire-iReach/ -- The Global Cephalosporin Drugs Market 2015 – 2019 report says increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs.

Photo - http://photos.prnewswire.com/prnh/20151001/273051

The Complete 100 Pages Report the Global Civilian Drones Market 2015-2019 is available at http://www.rnrmarketresearch.com/global-cephalosporin-drugs-market-2015-2019-market-report.html. The report provides 57 Exhibits that support the Cephalosporin Drugs market research.

The analysts forecast global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

According to the Global Cephalosporin Drugs Market 2015 – 2019 report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market.

Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil.

The following companies are the key players in the Global Cephalosporin Drugs Market: Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz and Teva.

Other Prominent Vendors in the market are: Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, and Wockhardt.

Purchase a Single User License Copy of the Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=419239for US $3000.

Covered in this report

In this report, covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, this report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. This report includes a discussion of the key vendors operating in this market.

Market driver

• Special regulatory designation for pipeline molecules
• For a full, detailed list, view our report

Market challenge

• Development of drug resistance
• For a full, detailed list, view our report

Market trend

• Use of combination therapies
• For a full, detailed list, view our report

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Evolution of cephalosporin drugs
Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
Exhibit 04: General principles involved in use of antibiotics
Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
Exhibit 06: Number of cases of E.coli in the UK 2012-2014
Exhibit 07: Legislation relating to the use of antibiotics in the US
Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Global cephalosporin drugs market segment by generation
Exhibit 11: Overview of activity of different generations of cephalosporins
Exhibit 12: Evolution of different generations of cephalosporin drugs
Exhibit 13: Global cephalosporin drugs market segment by route of administration
Exhibit 14: Different generations of cephalosporin drugs by route of administration
Exhibit 15: Global cephalosporin drugs market segment by geography 2014
Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
Exhibit 18: Percentage share of cephalosporin market in Americas
Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
Exhibit 28: Allergan: Key takeaways
Exhibit 29: Astellas: Key takeaways
Exhibit 30: Bristol-Myers Squibb: Key takeaways
Exhibit 31: GSK: Key takeaways
Exhibit 32: Merck: Key takeaways
Exhibit 33: Pfizer: Key takeaways
Exhibit 34: Sandoz: Key takeaways
Exhibit 35: Teva Pharmaceuticals: Key takeaways
Exhibit 36: Allergan: Business segmentation by product revenue 2014
Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 38: Allergan: Geographical segmentation by revenue 2014
Exhibit 39: Astellas: Product segmentation by revenue 2015
Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
Exhibit 41: Astellas: Geographical segmentation by revenue 2015
Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
Exhibit 45: GSK: Business segmentation by revenue 2014
Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: GSK: Geographical segmentation by revenue 2014
Exhibit 48: Merck: Business segmentation by revenue 2014
Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 50: Merck: Geographical segmentation by revenue 2014

Explore Other Reports by Infiniti Research at http://www.rnrmarketresearch.com/publisher/Infiniti-Research-Limited.html.

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Media Contact: Ritesh Tiwari, RnRMarketResearch, 1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch